Search

Illumina Inc

Suletud

SektorTervishoid

187.92 -2.98

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

187.06

Max

195.43

Põhinäitajad

By Trading Economics

Sissetulek

-268M

-134M

Müük

68M

1.2B

P/E

Sektori keskmine

37.039

68.51

Aktsiakasum

1.31

Kasumimarginaal

-11.562

Töötajad

8,600

EBITDA

80M

330M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-0.66% downside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

29. okt 2026

Turustatistika

By TradingEconomics

Turukapital

1.3B

30B

Eelmine avamishind

190.9

Eelmine sulgemishind

187.92

Uudiste sentiment

By Acuity

22%

78%

58 / 340 Pingereas Healthcare

Illumina Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. aug 2026, 23:06 UTC

Illumina Inc shares are lower in after-market trading following Thursday's close, despite an initial uptick. No specific news was identified to explain the decline.

5. aug 2026, 19:52 UTC

Correlated Moves

Illumina shares are lower following disappointing first-quarter results and broader market declines. ADP's report on weak job growth has added to cautious sentiment.

4. aug 2026, 19:31 UTC

Correlated Moves

Illumina Inc's shares are higher today, reflecting a broader market trend as the Russell 2000 Index also advances. The stock is near its one-month range high.

3. aug 2026, 20:03 UTC

News

Illumina shares are lower today as Citigroup maintains a Sell rating and raises its price target to $113 amid mixed analyst sentiment.

31. juuli 2026, 23:06 UTC

News

Illumina Inc reported strong Q2 results and raised full-year guidance, yet shares declined in after-market trading from Friday's close of $202.95.

30. juuli 2026, 23:41 UTC

News
Social Media

Illumina Inc shares declined in after-market trading despite strong second-quarter results and raised full-year EPS guidance, reflecting concerns over falling net income.

29. juuli 2026, 23:26 UTC

Illumina Inc. shares declined after-market amid overall market volatility following the Federal Reserve's decision to maintain interest rates amid rising inflation concerns.

28. juuli 2026, 19:46 UTC

News

Illumina Inc. is acquiring contingent payments from its merger with Treeline Biosciences to enhance integration. Shares are trading higher since Monday's close.

27. juuli 2026, 23:26 UTC

Illumina Inc shares are lower in after-market hours, continuing a decline over the past three sessions with no specific news identified.

24. juuli 2026, 17:46 UTC

Illumina Inc's shares are lower today, hitting a mid-morning low. Broader market sentiment may be affected by recent volatility in oil prices.

22. juuli 2026, 19:31 UTC

News

Illumina Inc shares are lower amid a report citing stagnant sales and concerns over management's investment opportunities. The company may need acquisitions for growth.

21. juuli 2026, 20:02 UTC

Correlated Moves
News

Illumina Inc's shares are higher, supported by broader market momentum and anticipation of upcoming earnings from major companies. The Russell 2000 Index also advanced.

20. juuli 2026, 19:56 UTC

Correlated Moves

Illumina Inc shares declined during Monday's session, paralleling a drop in the ARK Genomic Revolution ETF amid broader market weakness.

17. juuli 2026, 19:06 UTC

Illumina Inc shares are lower today amid broader market declines, particularly in technology and semiconductor stocks, following significant selling pressure in Asia.

16. juuli 2026, 22:06 UTC

Illumina Inc shares are lower in after-market hours, tracking broader market declines amid geopolitical tensions and mixed economic indicators.

15. juuli 2026, 18:51 UTC

Illumina Inc shares declined Wednesday, pulling back from earlier gains. No specific news was identified to explain this movement amid broader positive market trends.

14. juuli 2026, 19:36 UTC

News

Illumina shares rise as Canaccord raises price target to $190.00, despite a patent ruling against the company in Germany.

10. juuli 2026, 20:06 UTC

Correlated Moves

Illumina Inc shares are lower amid a broader decline in the biotechnology sector. Market volatility is heightened due to geopolitical tensions involving the U.S. and Iran.

9. juuli 2026, 19:11 UTC

News
Correlated Moves

Illumina Inc. appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, contributing to a rise in shares amid sector gains.

8. juuli 2026, 20:04 UTC

Correlated Moves

Illumina Inc shares are lower today, influenced by declines in the Life Sciences Tools & Services sector and a drop in the Russell 2000 Index.

7. juuli 2026, 21:41 UTC

Illumina Inc. shares are higher in after-market trading, reflecting ongoing strength despite earlier session pullbacks and broader caution in the technology sector.

6. juuli 2026, 19:52 UTC

Social Media
News

Evercore ISI raised its price target on Illumina to $200, maintaining an Outperform rating. Shares are trading higher amid positive sentiment and social media discussions.

2. juuli 2026, 23:06 UTC

Correlated Moves

Illumina Inc shares declined in after-market trading, reflecting broader trends despite positive movements in European equity indices, including a rise in the DAX.

1. juuli 2026, 20:03 UTC

News

Piper Sandler raised Illumina's price target to $200, contributing to shares trading higher today. The company also expanded its board with a new appointment.

30. juuni 2026, 20:01 UTC

News
Social Media

Illumina Inc shares are lower as Roche launches a competing gene sequencer at a lower price, challenging Illumina's market share in genetic testing technology.

29. juuni 2026, 23:16 UTC

Illumina Inc shares are lower in after-market trading, with no specific news identified to explain the movement. Broader U.S. equities show mixed performance.

26. juuni 2026, 23:16 UTC

Illumina Inc shares are trading lower in after-market hours. Broader market concerns over rising interest rates and inflation may be influencing investor behavior.

25. juuni 2026, 23:26 UTC

Illumina Inc shares are higher in after-market trading, reflecting strong performance above their 20-day moving average despite no specific news driving the move.

24. juuni 2026, 20:02 UTC

News
Social Media

Illumina Inc. shares are higher amid gains in the Life Sciences Tools & Services sector. Barclays raised its price target to $145 from $122.

23. juuni 2026, 22:46 UTC

Illumina Inc shares are higher in after-market trading, reflecting a notable advance since Tuesday's close and strong performance near the upper end of its one-month range.

Võrdlus sarnastega

Hinnamuutus

Illumina Inc Prognoos

Hinnasiht

By TipRanks

-0.66% langus

12 kuu keskmine prognoos

Keskmine 192.44 USD  -0.66%

Kõrge 230 USD

Madal 113 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Illumina Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

16 ratings

8

Osta

5

Hoia

3

Müü

Sentiment

By Acuity

58 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
help-icon Live chat